Head-to-head · free

Moderna vs NanoViricides, Inc.

MRNA vs NNVC — return on capital, cash generation, margins and balance sheet side by side.

MRNA

0 / 2

measures where MRNA leads

NNVC

2 / 2

measures where NNVC leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureMRNA · FY2025NNVC · FY2026
Revenue$1.9B—
Net income(2.8B)(8.2M)
Revenue growth (yearly, multi-year)-43.0%—
Free cash flow(2.1B)(7.8M)
Free cash flow margin-106.2%—
Net cash / (debt)——
ROIC——
Return on equity-28.9%—
Gross margin54.8%—
Operating margin-159.9%—
Net debt / EBITDA0.70x—

Figures are as reported by each company; latest fiscal year shown.

Where Moderna's cash went (FY2025)

Capital spending
$192.0M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full MRNA profile →

Where NanoViricides, Inc.'s cash went (FY2026)

Capital spending
$84317
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full NNVC profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons